Main Uses of Microcid

Microcid is a topical antimicrobial treatment primarily utilized for the management of various skin infections. Its active properties are designed to address conditions where bacteria or other microorganisms have compromised the skin barrier.

Primary Indications

• Pyoderma: The treatment of primary skin infections characterized by the presence of pus, such as impetigo or folliculitis.
• Infected Dermatitis: Managing secondary infections that occur as complications of existing skin conditions like eczema or seborrheic dermatitis.
• Wound Care: Application on minor cuts, abrasions, or burns that have become infected or are at a high risk of bacterial colonization.
• Ulcerated Skin: Assisting in the management of infected skin ulcers to help stabilize the localized environment of the wound.

Therapeutic Benefits

Microcid functions by inhibiting the growth and reproduction of sensitive microorganisms on the skin's surface. This action provides several clinical benefits for the recovery process:

Eradication of Pathogens

By targeting the specific bacteria responsible for the infection, the treatment helps to clear the underlying cause of the skin irritation. This is particularly effective against common Gram-positive bacteria.

Reduction of Inflammatory Symptoms

As the microbial load decreases, the secondary symptoms associated with infection typically subside. This includes a reduction in localized redness, swelling, and warmth at the site of application.

Support for Natural Healing

By controlling the presence of harmful bacteria, Microcid helps create a cleaner environment that allows the skin's natural regenerative processes to occur more efficiently. This helps prevent the infection from spreading to deeper tissues or adjacent areas of the body.

Regulatory References

1. NIH MedlinePlus overview

Microcid (Indomethacin) eligibility is strictly defined by official regulatory labeling, which establishes specific conditions and population groups that must not use the medicine, as well as those who require conditional use or special caution.

Absolute Contraindications

Microcid is strictly contraindicated and must not be used by patients who have a known hypersensitivity to the drug or a history of allergic reactions (such as asthma) after taking aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). It is also prohibited for use in the setting of Coronary Artery Bypass Graft (CABG) surgery, for those with active gastrointestinal ulceration or bleeding, and for patients with severe uncontrolled heart failure or renal impairment.

Pregnancy and Age Restrictions

The medicine is contraindicated in women during the third trimester of pregnancy (starting at 30 weeks gestation) and is not recommended for women who are breastfeeding. For children younger than 14 years of age, the safety and efficacy of the oral formulations have not been established. Older adults may use the medicine but require greater care due to an increased risk of serious adverse reactions.

Conditional Use Requirements

Use is only allowed with extreme caution in patients with a prior history of peptic ulcer disease or GI bleeding. Caution is also advised for patients with hepatic impairment, hypertension, or certain neurological disorders (such as epilepsy), as the medicine may aggravate these conditions.

Interactions with other medicines and products

This section summarizes information documented in official government regulatory sources regarding the interaction profile of Microcid (Indomethacin).

Interaction Classifications

Official labeling defines interactions primarily by the risk of pharmacokinetic or pharmacodynamic alteration of co-administered substances.

Interaction Type	Examples of Interacting Categories/Substances
Increased Bleeding Risk	Anticoagulants, Antiplatelet agents (e.g., Aspirin), Selective Serotonin Reuptake Inhibitors (SSRIs), Corticosteroids
Altered Drug Exposure	Digoxin, Lithium, Methotrexate, Cyclosporine
Diminished Therapeutic Effect	Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Beta-Blockers, Diuretics (e.g., Furosemide, Thiazides)

Regulatory Constraints and Monitoring

Co-administration with certain medicinal products requires constraints, primarily focused on patient monitoring and avoidance. The drug may diminish the blood pressure-lowering effect of Antihypertensives and the water-excreting effect of Diuretics, requiring vital sign monitoring.

Co-administration with Lithium and Digoxin can increase their serum concentrations, necessitating monitoring of serum levels. Concomitant use with analgesic doses of Aspirin is generally discouraged. Alcohol must be avoided due to the potential for increased risk of gastrointestinal issues. In patients who are elderly, volume-depleted, or have existing renal impairment, caution is required, as co-administration with ACE Inhibitors or ARBs may lead to a deterioration of renal function.

Enzyme Inhibition and Eicosanoid Regulation

Microcid's core mechanism involves functioning as a non-selective inhibitor of Cyclooxygenase (COX) enzymes, targeting both the inducible (COX-2) and constitutive (COX-1) forms. This interaction prevents the initial step in the synthesis of prostaglandins from arachidonic acid. This molecular action modifies an early step in the eicosanoid pathway, leading to a physiological decrease in chemical mediators that promote inflammation and nociceptive signaling.

---

Influencing Thermoregulation and Homeostatic Processes

The drug's effect on prostaglandin production occurs across multiple systems. Peripherally, inhibition reduces local mediator levels at the tissue site. Centrally, the mechanism influences enzyme activity in the brain's hypothalamus. This dual action alters the body's thermoregulatory center, resulting in a lower body temperature set-point, and modifies the transmission of nociceptive signals. Furthermore, the inhibition of constitutive COX-1 activity extends to pathways that regulate gastrointestinal mucosal integrity and renal blood flow.

Microcid (Indomethacin) is administered via the oral route, commonly using immediate-release capsules (25 mg, 50 mg) or 75 mg extended-release capsules, and is also approved for rectal administration via suppositories. The primary principle governing its administration is the use of the lowest effective dosage for the shortest duration necessary, particularly for chronic inflammatory conditions.

The standard adult initial oral dosing for chronic conditions, such as rheumatoid arthritis, starts at 25 mg taken two or three times a day. If clinical need dictates, the dosage may be cautiously increased in 25 mg or 50 mg increments at weekly intervals up to a maximum daily dose of 200 mg for the immediate-release form. The extended-release capsule is typically administered once or twice daily to provide a sustained dosage.

For acute, severe episodes like acute gouty arthritis, the labeled regimen is 50 mg three times a day using the immediate-release capsule. This high-dose regimen is required to be rapidly discontinued once acute symptoms subside. Administration rules for older adults emphasize greater care and adherence to the lowest effective dose for the shortest duration.

All oral formulations must be administered with food or immediately after meals to improve administration tolerance. A key procedural constraint is that extended-release capsules must be swallowed whole and should not be crushed, broken, or chewed. If a scheduled dose is missed, it is generally recommended to skip the missed dose and continue with the regular schedule, without doubling the subsequent dose.

Research Evidence / Overview of Studies for Microcid

Evidence for Use in Chronic Inflammatory Arthritis

The research structure for Microcid's use in chronic inflammatory conditions, such as Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis, includes short-term Randomized Controlled Trials (RCTs) and various observational studies. Researchers designed these studies to examine patient-reported outcomes describing perceived discomfort and functional measures related to daily activity level. Within the research setting, studies tracked symptom intensity or variability over defined time intervals. Findings describe patterns observed in the studies related to outcomes related to physical discomfort and how joint mobility or function was measured in the observed populations.

Evidence for Use in Acute Inflammatory Flares

Research exploring Microcid's use in acute episodes, such as a painful gout attack or acute bursitis/tendinitis, generally consists of Very Short-term RCTs and systematic analyses. These studies were conducted during periods of increased symptom activity, specifically examining outcomes describing episodic or acute changes. This research contributes to understanding short-term symptom patterns that may occur when focusing on acute symptom patterns. The primary uncertainty here is driven by the nature of the research itself: follow-up durations were brief, aligning with the immediate goal of acute symptom resolution.

Research Gaps and Areas of Uncertainty

Long-term effects are not fully established, as the research structure focuses heavily on symptomatic relief. Evidence is limited regarding the effect on underlying joint structure or disease progression, as the core research tracked symptom scores rather than biological markers of the condition. Furthermore, sample sizes were modest in some of the older trials, and evidence quality varies across studies. The research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Indomethacin Drug Information - MedlinePlus (NIH)
2. WHO Model List of Essential Medicines

Common questions about Microcid (FAQ)

Q: What are the most common reason patients stop taking Microcid?

Official documents show that the most frequently reported adverse reactions, occurring in 3% or more of patients in clinical trials, include headache, dizziness, dyspepsia (indigestion), and nausea. The official documents do not explicitly state reasons for stopping, but these are the most common adverse reactions reported in trials.

---

Q: Does Microcid require any special monitoring while being used?

Regulatory guidelines advise that certain health parameters should be monitored while taking this medicine. Blood pressure monitoring is appropriate during initiation and therapy, and that kidney function monitoring is advised for patients with certain pre-existing conditions. Additionally, monitoring of hemoglobin or hematocrit is advised if signs of anemia are present.

---

Q: Are there specific warnings for women who could become pregnant while using Microcid?

Official product information indicates that the use of NSAIDs like this medicine is generally not recommended for women who are attempting to conceive. This is because research suggests the medicine may have the potential to impair female fertility.

---

Q: What are the common signs of an allergic reaction to Microcid?

Documented signs of serious allergic reactions (hypersensitivity) include a rash, urticaria (hives), and swelling of the face or throat (angioedema). Other severe reactions noted in regulatory documents include difficulty breathing and acute anaphylaxis.

---

Q: Is Microcid generally considered safe for people over 75?

Official safety profiles indicate that elderly patients should be managed with special consideration due to their greater risk profile. This is because official documents indicate that this population is at an increased risk for serious gastrointestinal adverse events, such as internal bleeding or perforation.

---

Q: What are the general rules for stopping the use of Microcid?

Regulatory guidelines emphasize using the product for the shortest duration possible at the lowest effective level. For acute symptoms, official documents indicate that the prescribed regimen should be rapidly discontinued once the acute flare subsides.

---

Q: Are there any known issues with driving or operating machinery while using Microcid?

Official product information documents that common Central Nervous System (CNS) effects can occur. These include feelings of dizziness, lightheadedness, drowsiness, or decreased alertness.

---

Q: Does Microcid change how other medicines are absorbed?

Regulatory text mentions that the medicine can lead to altered exposure of some co-administered drugs. This may result in elevated serum concentrations (higher levels in the blood) of certain medicines, such as Lithium and Digoxin.

---

Q: What is the most important safety information to be aware of when using Microcid?

According to the FDA Boxed Warning, the most critical safety information concerns the risks of serious cardiovascular thrombotic events (like heart attack or stroke) and serious gastrointestinal adverse events (including bleeding, ulceration, and perforation of the stomach or intestines). Regulatory sources indicate these risks can occur early in treatment and are associated with increased risk over time.

---

Q: How long does the effect of Microcid typically last?

Official pharmacokinetic data describes the duration of the active ingredient's presence in the body. The mean elimination half-life of the active compound is estimated to be approximately 4.5 hours.

---

Q: How quickly does Microcid usually begin to take effect?

For immediate-release oral formulations, the active ingredient reaches peak plasma concentrations in about two hours. For chronic or severe arthritis, full therapeutic effects in clinical studies may take several weeks to become fully apparent.

---

Q: Can Microcid cause problems with sleep?

Yes, official safety documents list problems related to sleep as documented adverse reactions. These include the uncommon occurrence of insomnia as well as general sleepiness or drowsiness.

---

Q: Is Microcid a controlled substance?

No, the official drug labeling confirms that the medicine is not scheduled by the DEA (Drug Enforcement Administration).

---

Q: What is the shelf life of Microcid tablets?

Regulatory documents often specify the dating for product potency. The shelf life for the tablets is stated to be 36 months (three years) from the date of manufacture.

---

Q: Is Microcid known to cause changes in weight?

Official safety profiles document adverse reactions related to fluid balance. These include the potential for fluid retention and weight gain due to the medicine's documented effects on kidney function.

---

Q: What is the definition of a 'serious' adverse event according to Microcid's regulatory documents?

While regulatory sources do not provide a formal dictionary definition, they classify events as serious if they are potentially life-threatening or require hospitalization. Examples detailed in the warnings include major events like myocardial infarction (heart attack), stroke, and gastrointestinal bleeding.

Storage and Disposal of Microcid

Microcid (Indomethacin capsules) must be handled and stored according to strict regulatory guidelines to maintain potency and ensure safety.

Required Storage Conditions

Item	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C), protected from excess heat.
Protection	Keep away from light and moisture; do not freeze.
Container	Keep in the original container and ensure it is tightly closed
Child Safety	Must be stored out of the sight and reach of children; always lock safety caps.

Disposal Instructions

Disposal of unused or expired Microcid should primarily utilize an official drug take-back program. If a take-back program is unavailable, the medicine should be mixed with an unappealing substance (like dirt or coffee grounds) and placed in a sealed container before discarding in the household trash. Do not dispose of the medicine by flushing it down a toilet or pouring it down a drain.